ALKS
Alkermes plc
Halal Rating :
Last Price
$29.48
Last updated:
Market Cap
-
7D Change
3.99%
1 Year Change
3.58%
Company Overview
Industries
Exchange
Next Earnings Date
Alkermes plc is a global biopharmaceutical company that develops innovative medicines in the fields of neuroscience and oncology. The company focuses on treating complex conditions like schizophrenia, depression, and addiction. Their key products include LYBALVI®, ARISTADA®, and VIVITROL®.
The company develops, manufactures, and commercializes pharmaceutical products through proprietary technologies and research facilities. They have a strong focus on central nervous system (CNS) disorders and are expanding into cancer treatment.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $378.14m | $279.39m | - | $6.0m | 0.00% | 2.15% |
| June 30, 2024 | $399.13m | $295.2m | - | $5.95m | 0.00% | 2.02% |
| March 31, 2024 | $350.37m | $313.04m | - | $5.98m | 0.00% | 1.91% |
Company Impact
Help us evaluate Alkermes plc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.